Edgewise Therapeutics had its Relative Strength (RS) Rating upgraded from 69 to 72 Monday — a welcome improvement, but still shy of the 80 or higher score you prefer to see.
IBD's unique RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners often have an RS Rating north of 80 in the early stages of their moves. See if Edgewise Therapeutics can continue to show renewed price strength and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Edgewise Therapeutics is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could kick off a new climb.
Edgewise Therapeutics showed 0% EPS growth last quarter. Sales increased 0%.
The company earns the No. 155 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Krystal Biotech and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
